APOA1 Human
Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Apolipoprotein A-I Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 243 amino acids and having a molecular mass of 28.1kDa.
The APOA1 is purified by proprietary chromatographic techniques.
Product Specs
Recombinant human Apolipoprotein A-I, expressed in E. coli, is a single, non-glycosylated polypeptide chain comprising 243 amino acids. It possesses a molecular weight of 28.1 kDa. The purification of APOA1 is achieved through proprietary chromatographic methods.
The APOA1 protein solution was sterile filtered using a 0.2 µm filter and subsequently lyophilized from a concentrated solution in phosphate-buffered saline (PBS) at pH 7.4.
To reconstitute the lyophilized APOA1, it is recommended to dissolve it in sterile 18 MΩ-cm H₂O at a concentration of at least 100 µg/ml. This solution can then be further diluted in other aqueous solutions as needed.
The purity of Apolipoprotein A-I is determined to be greater than 98.0% using the following methods:
(a) Reverse-phase high-performance liquid chromatography (RP-HPLC) analysis.
(b) Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
DEPPQSPWD RVKDLATVYV DVLKDSGRDY VSQFEGSALG KQLNLKLLDN WDSVTSTFSK LREQLGPVTQ EFWDNLEKET EGLRQEMSKD LEEVKAKVQP YLDDFQKKWQ EEMELYRQKV EPLRAELQEG ARQKLHELQE KLSPLGEEMR DRARAHVDAL RTHLAPYSDE LRQRLAARLE ALKENGGARL AEYHAKATEH LSTLSEKAKP ALEDLRQGLL PVLESFKVSF LSALEEYTKK LNTQ.
Product Science Overview
Apolipoprotein A-I (ApoA-I) is a major protein component of high-density lipoprotein (HDL) particles in human plasma. It plays a crucial role in lipid metabolism and is essential for the reverse transport of cholesterol from tissues to the liver for excretion. Recombinant human ApoA-I is produced using various expression systems, such as Escherichia coli, to ensure high purity and functionality for research and therapeutic applications .
ApoA-I is a single, non-glycosylated polypeptide chain consisting of 243 amino acids and has a molecular mass of approximately 28.1 kDa . It is encoded by the APOA1 gene in humans . The protein is known for its ability to promote cholesterol efflux from tissues, acting as a cofactor for the enzyme lecithin cholesterol acyltransferase (LCAT), which is involved in the esterification of cholesterol .
ApoA-I is the principal component of HDL, often referred to as “good cholesterol.” It plays a significant role in the prevention of atherosclerosis through the process of reverse cholesterol transport (RCT). This process involves the transfer of cholesterol from peripheral tissues back to the liver for excretion, thereby reducing the risk of plaque formation in arteries .
Recombinant human ApoA-I has shown promise in various therapeutic applications, particularly in the treatment of cardiovascular diseases. One notable variant, ApoA-I Milano, is a natural mutant of ApoA-I that has demonstrated the ability to clear arterial wall thrombus deposits and alleviate acute myocardial ischemia . This makes it a promising candidate for treating atherosclerotic diseases without significant toxic or side effects .
The production of recombinant human ApoA-I typically involves the use of expression systems such as Escherichia coli. The protein is purified using proprietary chromatographic techniques to achieve high purity levels, often exceeding 95% . The purified protein is suitable for various applications, including SDS-PAGE and sELISA .
